Last reviewed · How we verify
Propofol-Fentanyl-Dexmedetomidine
Propofol-Fentanyl-Dexmedetomidine is a Small molecule drug developed by Ain Shams University. It is currently in Phase 1 development.
At a glance
| Generic name | Propofol-Fentanyl-Dexmedetomidine |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Experienced sedation beyond postanesthesia care unit
- Oxygen requirement beyond postanesthesia care unit
- Experienced vomiting
- Severe bradycardia
- Experienced pruritis
- nausea
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Transition From Acute to Chronic Opioid Use and Chronic Pain (EARLY_PHASE1)
- A Comparative Study Between Combination of Propofol and Dexmedetomidine Versus Propofol Alone in Anesthesia for Rigid Bronchoscopy by Using the Patient State Index Monitor (PHASE4)
- Cognitive Function in Geriatric Colonoscopy Patients
- Inhalational Agents Versus Dexmedetomidine for Maintenance of General Anesthesia (NA)
- Effect of Total Intravenous Anesthesia vs Inhalational Anesthesia on the Level of Inflammatory Markers (NA)
- Effect of Dexmedetomidine on Tear Production in Angioplasty Patients (NA)
- A Pilot Study of Local Anesthesia for Inguinal Hernia Surgery in Older Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propofol-Fentanyl-Dexmedetomidine CI brief — competitive landscape report
- Propofol-Fentanyl-Dexmedetomidine updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Propofol-Fentanyl-Dexmedetomidine
What is Propofol-Fentanyl-Dexmedetomidine?
Propofol-Fentanyl-Dexmedetomidine is a Small molecule drug developed by Ain Shams University.
Who makes Propofol-Fentanyl-Dexmedetomidine?
Propofol-Fentanyl-Dexmedetomidine is developed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).
What development phase is Propofol-Fentanyl-Dexmedetomidine in?
Propofol-Fentanyl-Dexmedetomidine is in Phase 1.
What are the side effects of Propofol-Fentanyl-Dexmedetomidine?
Common side effects of Propofol-Fentanyl-Dexmedetomidine include Experienced sedation beyond postanesthesia care unit, Oxygen requirement beyond postanesthesia care unit, Experienced vomiting, Severe bradycardia, Experienced pruritis, nausea.